Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

PMID:
29066505
2.

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.

Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J.

BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8.

3.

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.

Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G.

BMC Cancer. 2014 Sep 10;14:660. doi: 10.1186/1471-2407-14-660.

4.

Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.

Nam HJ, Im SA, Oh DY, Elvin P, Kim HP, Yoon YK, Min A, Song SH, Han SW, Kim TY, Bang YJ.

Mol Cancer Ther. 2013 Jan;12(1):16-26. doi: 10.1158/1535-7163.MCT-12-0109. Epub 2012 Nov 9.

5.

Nonclinical selection criteria for maximizing yield of nucleic acid amplification tests in tuberculosis diagnosis.

Han LL, Elvin P, Bernardo J.

J Clin Microbiol. 2012 Aug;50(8):2592-5. doi: 10.1128/JCM.00871-12. Epub 2012 May 23.

6.

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.

Boult JK, Jamin Y, Jacobs V, Gilmour LD, Walker-Samuel S, Halliday J, Elvin P, Ryan AJ, Waterton JC, Robinson SP.

Br J Cancer. 2012 Jun 5;106(12):1960-6. doi: 10.1038/bjc.2012.208. Epub 2012 May 17.

7.

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J.

Clin Cancer Res. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. Epub 2010 Aug 30.

8.

Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.

Arcaroli JJ, Touban BM, Tan AC, Varella-Garcia M, Powell RW, Eckhardt SG, Elvin P, Gao D, Messersmith WA.

Clin Cancer Res. 2010 Aug 15;16(16):4165-77. doi: 10.1158/1078-0432.CCR-10-0066. Epub 2010 Aug 3.

9.

Inhibition of Src impairs the growth of met-addicted gastric tumors.

Bertotti A, Bracco C, Girolami F, Torti D, Gastaldi S, Galimi F, Medico E, Elvin P, Comoglio PM, Trusolino L.

Clin Cancer Res. 2010 Aug 1;16(15):3933-43. doi: 10.1158/1078-0432.CCR-10-0106. Epub 2010 Jul 13.

10.

Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.

Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-Skinner LA, Martin KH, Frederick B, Rothschild BL, Raben D, Elvin P, Green TP, Weed SA.

J Cancer Sci Ther. 2009 Nov 30;1(2):52-61.

11.

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.

Green TP, Fennell M, Whittaker R, Curwen J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM, Wilkinson RW, Elvin P, Boyer B, Carragher N, Plé PA, Bermingham A, Holdgate GA, Ward WH, Hennequin LF, Davies BR, Costello GF.

Mol Oncol. 2009 Jun;3(3):248-61. doi: 10.1016/j.molonc.2009.01.002. Epub 2009 Feb 7.

12.

Src inhibitors in early breast cancer: a methodology, feasibility and variability study.

Jones RJ, Young O, Renshaw L, Jacobs V, Fennell M, Marshall A, Green TP, Elvin P, Womack C, Clack G, Dixon JM.

Breast Cancer Res Treat. 2009 Mar;114(2):211-21. doi: 10.1007/s10549-008-9997-1. Epub 2008 Apr 14.

PMID:
18409068
13.

Regional copy number-independent deregulation of transcription in cancer.

Stransky N, Vallot C, Reyal F, Bernard-Pierrot I, de Medina SG, Segraves R, de Rycke Y, Elvin P, Cassidy A, Spraggon C, Graham A, Southgate J, Asselain B, Allory Y, Abbou CC, Albertson DG, Thiery JP, Chopin DK, Pinkel D, Radvanyi F.

Nat Genet. 2006 Dec;38(12):1386-96. Epub 2006 Nov 12. Erratum in: Nat Genet. 2008 Mar;40(3):373.

PMID:
17099711
14.

Tumour invasion and metastasis: challenges facing drug discovery.

Elvin P, Garner AP.

Curr Opin Pharmacol. 2005 Aug;5(4):374-81. Review.

PMID:
15955738
15.

Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas.

Reyal F, Stransky N, Bernard-Pierrot I, Vincent-Salomon A, de Rycke Y, Elvin P, Cassidy A, Graham A, Spraggon C, Désille Y, Fourquet A, Nos C, Pouillart P, Magdelénat H, Stoppa-Lyonnet D, Couturier J, Sigal-Zafrani B, Asselain B, Sastre-Garau X, Delattre O, Thiery JP, Radvanyi F.

Cancer Res. 2005 Feb 15;65(4):1376-83.

16.

Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor.

Bernard-Pierrot I, Ricol D, Cassidy A, Graham A, Elvin P, Caillault A, Lair S, Broët P, Thiery JP, Radvanyi F.

Oncogene. 2004 Dec 9;23(57):9201-11.

PMID:
15516981
17.

Estimated costs of false laboratory diagnoses of tuberculosis in three patients.

Northrup JM, Miller AC, Nardell E, Sharnprapai S, Etkind S, Driscoll J, McGarry M, Taber HW, Elvin P, Qualls NL, Braden CR.

Emerg Infect Dis. 2002 Nov;8(11):1264-70.

18.

Rectal cancer: evaluation of staging with endosonography.

Lindmark GE, Kraaz WG, Elvin PA, Glimelius BL.

Radiology. 1997 Aug;204(2):533-8.

PMID:
9240549
19.

Plasminogen activator inhibitor type 2 in breast cancer.

Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N, Duffy MJ.

Br J Cancer. 1997;76(5):622-7.

20.

Vascular endothelial growth factor stimulates protein kinase C-dependent phospholipase D activity in endothelial cells.

Seymour LW, Shoaibi MA, Martin A, Ahmed A, Elvin P, Kerr DJ, Wakelam MJ.

Lab Invest. 1996 Sep;75(3):427-37.

PMID:
8804365
21.

Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer.

Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermott E, Fennelly JJ, O'Higgins N.

Enzyme Protein. 1996;49(1-3):85-93.

PMID:
8796999
23.

Amplification and sequencing of genomic breakpoints located within the M-bcr region by Vectorette-mediated polymerase chain reaction.

Mills KI, Sproul AM, Ogilvie D, Elvin P, Leibowitz D, Burnett AK.

Leukemia. 1992 May;6(5):481-3.

PMID:
1317490
24.

Walking, cloning, and mapping with yeast artificial chromosomes: a contig encompassing D21S13 and D21S16.

Butler R, Ogilvie DJ, Elvin P, Riley JH, Finniear RS, Slynn G, Morten JE, Markham AF, Anand R.

Genomics. 1992 Jan;12(1):42-51.

PMID:
1733862
25.

Detection of mRNA for ribosomal phosphoprotein P2 in normal colon and colonic tumours by in situ hybridization.

Harvie R, Elvin P, McArdle C, Morten JE, McNicol AM.

J Pathol. 1991 May;164(1):67-73.

PMID:
2056390
26.

Use of angiographic needles with or without stylets: pathologic assessment of vessel walls after puncture.

Frood LR, Smith DC, Pappas JM, Elvin PK, Westengard JC, Saukel GW.

J Vasc Interv Radiol. 1991 May;2(2):269-72.

PMID:
1799765
27.

Localisation of a cDNA clone for human cytokeratin 18 to chromosome 17p11-p12 by in situ hybridisation.

Heath P, Elvin P, Jenner D, Gammack A, Morten J, Markham A.

Hum Genet. 1990 Oct;85(6):669-70. No abstract available.

PMID:
1699878
28.

Isolation of cDNA clones using yeast artificial chromosome probes.

Elvin P, Slynn G, Black D, Graham A, Butler R, Riley J, Anand R, Markham AF.

Nucleic Acids Res. 1990 Jul 11;18(13):3913-7.

29.

Human cDNA sequence homologous to the mouse LLRep3 gene family.

Slynn G, Jenner D, Potts W, Elvin P, Morten JE, Markham AF.

Nucleic Acids Res. 1990 Feb 11;18(3):681. No abstract available.

30.

A sequence previously identified as metastasis-related encodes an acidic ribosomal phosphoprotein, P2.

Sharp MG, Adams SM, Elvin P, Walker RA, Brammar WJ, Varley JM.

Br J Cancer. 1990 Jan;61(1):83-8.

32.
33.

Adhesive properties of the B16 melanoma.

Elvin P, Evans CW.

Prog Clin Biol Res. 1985;172A:537-47. No abstract available.

PMID:
3991696
34.
35.

Cell adhesion and experimental metastasis: a study using the B16 malignant melanoma model system.

Elvin P, Evans CW.

Eur J Cancer Clin Oncol. 1984 Jan;20(1):107-14.

PMID:
6537909
36.

Adaptation of the Boyden chamber to flow conditions: rheological effects on chemotaxis.

Elvin P, Drake BL, Evans CW.

J Immunol Methods. 1983 Nov 25;64(3):295-301.

PMID:
6366056
37.
38.
39.

Anti-tumour activity of novel adducts of ascorbic acid with aldehydes.

Elvin P, Slater TF.

Eur J Cancer Clin Oncol. 1981 Jul;17(7):759-65. No abstract available.

PMID:
7199470

Supplemental Content

Support Center